Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1

Status

Unknown 2

Sponsor Class

OTHER 49INDUSTRY 13OTHER_GOV 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 3Thoracic 2Breast 2Head & Neck 1Genitourinary 1

Conditions

EGFR Positive Non-small Cell Lung Cancer 1Carcinoma, Non-Small-Cell Lung 1

Interventions

Pemetrexed 13Cisplatin 12Carboplatin 12Drug Therapy 10Gemcitabine 8Gefitinib 8Docetaxel 8camrelizumab 5apatinib 5Radiotherapy 5Paclitaxel 5Nivolumab 5Irinotecan 5Erlotinib Hydrochloride 5Endostatins 5tislelizumab 4pembrolizumab 4endostar protein 4Simvastatin 4Bevacizumab 4anlotinib 3Platinum Compounds 3Immune Checkpoint Inhibitors 3Etoposide 3toripalimab 2surufatinib 2olaparib 2durvalumab 2atezolizumab 2Topotecan 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
OTHER_GOV × toripalimab × Thoracic × Clear all
NCT06208033 2024-01-17

SMET12 and Toripalimab Combined Chemotherapy in Patients With EGFR Positive Advanced Non-small Cell Lung Cancer (NSCLC)

Fujian Cancer Hospital

Phase EARLY_PHASE1 Unknown
40 enrolled
Thoracic

EGFR Positive Non-small Cell Lung Cancer

NCT04613804 2020-11-03

Toripalimab as Maintenance Therapy in Patients With Driver-gene Negative Advanced NSCLC After First-line Chemotherapy

Fujian Cancer Hospital

Phase 2 Unknown
30 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡